GFAP and cerebrovascular disorder: After accounting for time, compared to the control group, there were no significant differences in S-100β (ng/L; 5.5 [95% CI −25.4, 36.5], P = 0.726), glial fibrillary acid protein (ng/mL; −1.29 [95% CI −6.3, 3.7], P = 0.615), neuron specific enolase (ng/mL; −3.0 [95% CI −7.2, 1.3], P = 0.169), or matrix metalloproteinase-9 (ng/mL; 30.9 [95% CI −138, 199], P = 0.719) in the cerebrovascular disease group.